SCHEMBL14735159

SCHEMBL14735159

Cc1[nH]c2ccccc2c1C=C1Oc2cc(O)ccc2C1=O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 6/20 0.71
MTOR P42345 6/20 0.71
TYR P14679 3/20 0.57
MAOA P21397 3/20 0.55
MAOB P27338 3/20 0.55
CISD1 Q9NZ45 2/20 0.55
PIK3CG P48736 4/20 0.53
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
HASPIN Q8TF76 1/20 0.50
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
USP2 O75604 1/20 0.49
CASP3 P42574 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
KIT P10721 1/20 0.49
PTGS2 P35354 1/20 0.49
ELANE P08246 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14735156 1.00 PIK3CA (0.71) PIK3CAMTORTYRMAOAMAOB
SCHEMBL1428168 0.86 PIK3CA (0.63) PIK3CAMTORMAOAMAOBCISD1
SCHEMBL4322482 0.86 PIK3CA (0.63) PIK3CAMTORMAOAMAOBCISD1
SCHEMBL1428507 0.85 PIK3CA (0.72) PIK3CAMTORTYRMAOAMAOB
SCHEMBL4330707 0.85 PIK3CA (0.72) PIK3CAMTORTYRMAOAMAOB
SCHEMBL4328111 0.82 MEN1 (0.61) PIK3CAMTORTYRMAOAMAOB
SCHEMBL1428528 0.82 MEN1 (0.61) PIK3CAMTORTYRMAOAMAOB
SCHEMBL4325800 0.82 PIK3CA (0.74) PIK3CAMTORTYRMAOAMAOB
SCHEMBL1428537 0.82 PIK3CA (0.74) PIK3CAMTORTYRMAOAMAOB
SCHEMBL1428523 0.82 PIK3CA (0.74) PIK3CAMTORTYRMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2565192-B9 ANTICANCER AGENT UNIV TOKYO (JP) 2015-11-25 EP disclosed
US-9156827-B2 Anticancer agent THE UNIVERSITY OF TOKYO (JP) 2015-10-13 US disclosed
EP-2565192-B1 ANTICANCER AGENT UNIV TOKYO (JP) 2015-08-12 EP disclosed
US-20130102776-A1 ANTICANCER AGENT RIKEN (JP) 2013-04-25 US disclosed
EP-2565192-A1 ANTICANCER AGENT The University of Tokyo (JP) 2013-03-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130102776-A1 ANTICANCER AGENT PIM1, PIM3, PIM2 PIK3CA 942/4885MTOR 103/4885TYR 571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.